OakChart

Q32 Bio Inc

QTTBHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

9.20-0.13 (-1.39%)
2026-11-12 03:56 CET
Market cap
275.30 USD m
Revenue, TTM
53.74 USD m
Net income, TTM
32.25 USD m
Free cash flow, TTM
-20.07 USD m
EPS diluted, TTM
3.34
P/E
2.75
Compare

Price

QTTB against its 20, 50 and 200-day averages
2050200beatearnings
5.0010.0015.0020.0013.9M27.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26QTTBclose 9.2020-day 8.7150-day 9.39200-day 9.449.2052w high

61.0% under the 52-week high of 23.57 on 14 Jul 2026. 52-week low 1.91 on 20 Nov 2025. Last 15 sessions, 18.4% high to low

Volume 0.35× normal · the line is the 50-bar volume average

Profile

QTTB
52-week range, 34% of the way up
1.9023.57

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Employees24
IPOMar 28, 2018
Beta0.44
ATR, 14d0.57
Rel volume0.35
Short float28.89%
Insider own35.34%
Inst own58.68%

Snapshot

6 groups

Valuation

Index-
Market Cap275.30M
Enterprise Value-9.17M
Income32.25M
Sales53.74M
Book/sh9.62
Cash/sh9.68
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees24
IPOMar 28, 2018

Ratios

P/E2.75
Forward P/E-
PEG-
P/S5.12
P/B0.96
P/C0.95
P/FCF-
EV/EBITDA-0.49
EV/Sales-0.17
Quick Ratio56.33
Current Ratio56.33
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)3.34
EPS next Y-2.07
EPS next Q-0.28
EPS this Y-156.40%
EPS next Y-51.56%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y155.87% 81.85%
EPS Y/Y TTM197.18%
Sales Y/Y TTM-
EPS Q/Q56.56%
Sales Q/Q-
EarningsNov 04 BMO
EPS/Sales Surpr.20.42% -

Ownership

Insider Own35.34%
Insider Trans54.44%
Inst Own58.68%
Inst Trans14.63%
ROA18.17%
ROE23.96%
ROIC11.04%
Gross Margin99.35%
Oper. Margin34.20%
Profit Margin60.02%
SMA205.61%
SMA50-2.03%
SMA200-2.55%
Trades-

Technical

Shs Outstand29.89M
Shs Float19.35M
Short Float28.89%
Short Ratio8.17
Short Interest5.59M
52W High23.57 -60.97%
52W Low1.90 382.94%
Volatility6.21% 6.27%
ATR (14)0.57
RSI (14)52.40
Beta0.44
Rel Volume0.35
Avg Volume684.43K
Volume236,281

Performance

Perf Week2.56%
Perf Month14.14%
Perf Quarter-40.14%
Perf Half Y54.88%
Perf YTD177.11%
Perf Year265.08%
Perf 3Y-49.39%
Perf 5Y-91.29%
Perf 10Y-
Recom1.00
Target Price39.43
Prev Close9.33
Price9.20
Change %-1.39%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedLLeerink PartnersOutperform$40+334.8%
Sep 28, 2026InitiatedJJefferiesBuy$29+215.2%
Aug 24, 2026InitiatedMMorgan StanleyOverweight$34+269.6%
May 18, 2026InitiatedCCantor FitzgeraldOverweight
Feb 25, 2026InitiatedHH.C. WainwrightBuy$13+41.3%
Feb 11, 2025DowngradePPiper SandlerOverweight → Neutral$20 → $4-56.5%
Feb 11, 2025DowngradeBBMO Capital MarketsOutperform → Market Perform$22 → $3-67.4%
Dec 11, 2024DowngradeWWells FargoOverweight → Equal Weight$95 → $16+73.9%
Dec 11, 2024DowngradeRRaymond JamesStrong Buy → Outperform$90 → $22+139.1%
Dec 11, 2024DowngradeLLeerink PartnersOutperform → Market Perform$68 → $9-2.2%

Peers

Mkt cap
TickerCompanyMkt cap
NKTRNektar Therapeutics1.31B
ACRSAclaris Therapeutics Inc688.38M
EVMNEvommune Inc312.84M
ZURAZura Bio Ltd137.75M
ANABAnaptysBio Inc1.46B
ALMSAlumis Inc883.74M
IMAImageneBio Inc42.23M
ARQTArcutis Biotherapeutics Inc3.59B
INCYIncyte Corp24.92B
LLYLilly(Eli) & Co1352.12B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Morrison Jodie PopeCEOOct 06 '26Sale8.323,22126,798340,038Oct 14 05:30 PM
Kalowski LeeCFO and PresidentOct 06 '26Sale8.321,30110,824137,170Oct 14 05:30 PM
Violette Shelia M.Chief Scientific OfficerOct 06 '26Sale8.329177,629126,854Oct 14 05:30 PM
Morrison Jodie PopeCEOAug 25 '26Sale16.569,845163,033343,259Aug 27 04:10 PM
Kalowski LeeCFO and PresidentAug 25 '26Sale16.563,97265,776138,471Aug 27 04:10 PM
Violette Shelia M.Chief Scientific OfficerAug 25 '26Sale16.562,79846,335127,771Aug 27 04:10 PM
Manke IsaacDirectorJun 30 '26Option Exercise2.8053,521149,85953,521Jul 02 04:30 PM
Xu DiyongDirectorMay 28 '26Buy8.001,875,00015,000,0003,502,987Jun 01 09:15 PM
ORBIMED ADVISORS LLCDirectorMay 28 '26Buy8.001,875,00015,000,0003,502,987Jun 01 09:13 PM
Kalowski LeeCFO and PresidentFeb 25 '26Sale4.513,99518,03535,943Feb 27 07:00 PM
Morrison Jodie PopeCEOFeb 25 '26Sale4.519,89644,67589,104Feb 27 07:00 PM
Violette Shelia M.Chief Scientific OfficerFeb 25 '26Sale4.512,81512,70855,569Feb 27 07:00 PM
Morrison Jodie PopeCEODec 02 '25Sale3.4622,50677,87199,000Dec 04 07:00 PM
Kalowski LeeCFO and PresidentDec 02 '25Sale3.469,07231,39539,938Dec 04 07:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FDMFirst Trust Dow Jones Select Microcap Index FundAUM: 267.52M
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVUSAvantis U.S. Equity ETFAUM: 14.65B
ROSCHartford Multifactor Small Cap ETFAUM: 49.81M

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.260-0.327-0.2600.000.008
2026Q22026-08-05-0.440-0.542-0.4400.001.005
2026Q12026-05-05-0.540-0.680-0.5400.000.002
2025Q42026-03-104.580-0.8604.58553.740.003
2025Q32025-11-13-0.600-1.190-0.6040.000.002
2025Q22025-08-06-0.780-0.978-0.7780.000.002
2025Q12025-05-08-0.900-1.230-0.9040.000.002
2024Q42025-03-11-1.160-1.530-1.1650.000.003
2024Q32024-11-07-1.460-1.379-1.4570.000.004
2024Q22024-08-08-1.420-0.997-1.4190.000.003
2024Q12024-05-09-6.330-1.415-6.3280.000.002
2023Q42024-03-13-3.310-5.400-5.001-0.501
2023Q32023-11-14-10.260-7.560-10.2530.500.501
2023Q22023-08-14-10.980-8.505-10.9140.350.834
2023Q12023-05-11-9.000-9.540-8.9960.801.017
2022Q42023-03-09-10.800-8.860-10.7390.800.8310

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-44.460-46.645-44.4111.672.30
2020FY-50.400-51.165-50.4562.702.90
2021FY-31.140-30.060-31.18034.0033.82
2022FY-1.620-0.149-1.5703.212.95
2023FY-9.350-35.640-153.97-6.401.16
2024FY-6.580-5.612-6.5790.000.00
2025FY2.420-2.807-10.32053.740.00
2026FY--1.365--0.29
2027FY--2.069--0.71
2028FY--2.083--2.50
2029FY--1.576--61.05
2030FY-0.177--156.9

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-044000.500.002.00
2026Q4S2026-10-094000.500.002.00
2026Q4S2026-09-143000.670.002.00
2026Q4S2026-08-054000.500.002.00
2026Q4S2026-05-153000.670.002.00
2026Q4S2026-05-052000.000.000.00
2026Q4S2026-03-101000.000.000.00
2026Q4R2026-11-04210-0.30-0.32-0.27
2026Q4R2026-10-09200-0.30-0.33-0.27
2026Q4R2026-09-25100-0.33-0.33-0.33
2026Q4E2026-11-04851-0.29-0.35-0.21
2026Q4E2026-10-20801-0.30-0.36-0.23
2026Q4E2026-10-19811-0.30-0.36-0.23
2026Q4E2026-10-09822-0.30-0.36-0.23

Estimate history

EPS, annual-14.422-35.038-44.411-50.456-31.18-1.57-153.966-6.5792.4223.3426
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.457-1.165-0.904-0.778-0.6044.585-0.54-0.44-0.262
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual05.3221.6662.70233.9713.208-6.651053.73753.74
Period201720182019202020212022202320242025TTM
Sales, quarterly0000053.737000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.0792.0752.5062.7933.1753.1940.3612.19812.85829.892
Period201720182019202020212022202320242025MRQ
Shares, quarterly12.13912.19812.19812.19812.30412.85814.62923.73729.892
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue53.7453.740.00-6.653.2133.972.701.675.32
Cost of Goods Sold Incl. D&A0.350.390.490.502.609.54---
Gross Profit53.3953.35-0.49-7.150.6124.43---
Selling, General and Administrative Excl. Other35.0136.4465.6141.10133.89120.38124.06105.2963.96
Research and Development15.9419.1648.1431.7398.3593.08100.3989.4047.95
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income18.3816.90-66.10-48.26-133.28-95.95-130.26-109.94-59.93
Interest Expense-1.100.301.500.000.000.000.000.00
Unusual Expense0.15-0.40-17.396.190.000.000.00-0.00
Net Income Before Taxes32.2529.82-46.09-53.421.20-95.76-128.69-103.92-55.58
Income Taxes0.000.000.020.320.710.000.000.000.00
Consolidated Net Income32.2529.82-47.73-53.74-5.00-95.76-128.69-103.92-55.58
Net Income From Continuing Operations32.2529.82-47.73-53.74-5.00-95.76-128.69-103.92-55.58
Net Income32.2529.82-47.73-53.74-5.00-95.76-128.69-103.92-55.58
EPS (Recurring)0.952.40-7.84-141.55-1.57-31.18-50.46-44.41-35.04
EPS (Basic, Before Extraordinaries)3.352.42-5.12-153.97-1.57-31.18-50.46-44.41-35.04
EPS (Diluted)3.342.42-6.58-153.97-1.57-31.18-50.46-44.41-35.04
EBITDA18.7317.29-65.61-47.76-130.68-86.41-121.36-103.62-58.64
Non-Operating Income (Expense)15.2213.622.922.52134.480.181.576.034.35
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.605.253.461.1310.3117.2513.257.632.62
Price To Earnings Ratio2.752.75-------
Price To Sales Ratio5.240.76-30.4222.545.92191.83523.31119.96
Gross Margin99.3599.27-107.5018.9871.91---
Operating Margin34.2031.45-725.53-4,154.64-282.44-4,820.98-6,599.22-1,126.01
Net Margin60.0255.49-808.04-156.02-281.90-4,762.92-6,237.45-1,044.29
Shares Outstanding29.8912.8612.200.363.193.182.792.512.08
Market Capitalization275.30275.3041.9035.2072.43208.03567.50933.92835.34

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.0053.740.000.000.000.00
Cost of Goods Sold Incl. D&A0.080.090.090.090.090.090.120.12
Gross Profit-0.08-0.09-0.0953.65-0.09-0.09-0.12-0.12
Selling, General and Administrative Excl. Other10.589.037.637.777.499.0812.1114.41
Research and Development5.154.263.223.313.565.167.1210.54
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.66-9.12-7.7245.88-7.58-9.17-12.23-14.53
Interest Expense-0.800.200.200.300.300.30-
Unusual Expense0.000.150.000.000.000.601.500.20
Net Income Before Taxes-8.92-8.95-7.6157.73-7.39-9.49-11.03-14.17
Income Taxes0.000.000.000.000.000.000.000.02
Consolidated Net Income-8.92-8.95-7.6157.73-7.39-9.49-11.03-14.19
Net Income From Continuing Operations-8.92-8.95-7.6157.73-7.39-9.49-11.03-14.19
Net Income-8.92-8.95-7.6157.73-7.39-9.49-11.03-14.19
EPS (Recurring)-0.26-0.43-0.544.58-0.60-0.74-0.82-1.15
EPS (Basic, Before Extraordinaries)-0.26-0.44-0.544.60-0.60-0.78-0.90-1.16
EPS (Diluted)-0.26-0.44-0.544.58-0.60-0.78-0.90-1.16
EBITDA-10.58-9.03-7.6345.97-7.49-9.08-12.11-14.41
Non-Operating Income (Expense)1.741.120.3112.050.490.583.000.56
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.901.691.551.471.181.271.340.99
Price To Earnings Ratio2.754.782.79-----
Price To Sales Ratio5.244.821.680.78----
Gross Margin---99.83----
Operating Margin---85.38----
Net Margin---107.43----
Shares Outstanding29.8923.7414.6312.8612.3012.2012.2012.20
Market Capitalization275.30216.0293.9240.8524.1518.1720.1341.90

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments48.3077.9725.62175.03155.87217.43262.39214.74129.66
Short Term Receivables0.000.000.000.000.000.400.400.800.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets6.753.913.105.9936.041.733.796.151.94
Total Current Assets55.0581.8828.72181.01191.91219.56266.58221.69131.60
Net Property, Plant & Equipment6.087.098.0821.6417.8642.9042.7235.643.15
Total Investments and Advances0.653.255.6525.811.951.271.271.771.77
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets--221.56------
Other Assets0.000.124.610.000.000.000.000.001.00
Total Assets61.7892.3347.06228.47211.72263.74310.57259.09137.53
Short Term Debt Incl. Current Port. of LT Debt6.933.711.421.560.252.500.000.000.00
Accounts Payable0.882.993.471.142.374.722.6115.732.54
Other Current Liabilities3.549.779.2219.8714.6115.449.776.796.32
Total Current Liabilities11.3516.4614.1122.5817.2322.6612.3722.528.86
Long Term Debt8.4215.1949.4227.9223.6912.940.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities--221.56------
Other Liabilities0.0055.0055.000.001.1632.1439.6940.2230.36
Total Liabilities19.7686.66118.5350.4942.0767.7452.0662.7439.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.00111.440.000.000.000.000.00137.76
Common Equity42.015.67-182.92177.98169.65196.00258.51196.35-39.45
Total Shareholders Equity42.015.67-71.48177.98169.65196.00258.51196.3598.31
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity42.015.67-71.48177.98169.65196.00258.51196.3598.31
Total Liabilities & Stockholders Equity61.7892.3347.06228.47211.72263.74310.57259.09137.53
Book Value Per Share3.270.47-508.7355.7353.4370.19103.1494.61-18.97
Tangible Book Value Per Share3.270.47-508.7355.7353.4370.19103.1494.61-18.97
Full-Time Employees244279222420518712467
Price to Book Ratio0.962.280.400.351.232.903.614.293.83
Return on Assets38.70-23.96-39.01-2.27-40.28-44.82-36.48-28.03-39.53
Return on Equity125.06-121.36-100.92-2.88-52.38-56.63-45.86-37.72-56.69
Return on Invested Capital59.13-228.75--2.43-49.53-61.59-40.20-28.30-30.51
Quick Ratio4.854.972.048.0211.149.6921.549.8414.85
Current Ratio4.854.972.048.0211.149.6921.549.8414.85

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income32.2529.82-47.73-53.74-5.00-95.76-128.69-103.92-55.58
Depreciation0.350.390.490.502.609.548.906.321.29
Other Funds (Non Cash)-57.06-59.72-10.838.25-114.6118.2713.945.781.16
Funds from Operations-24.46-29.50-58.08-44.99-117.01-67.95-105.85-91.82-53.13
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.45-4.04-9.6426.323.35-41.8011.520.4610.56
Cash from Operating Activities-20.02-33.54-67.72-18.68-113.66-109.75-94.33-91.36-42.56
Capital Expenditures-0.050.00-0.07-0.01-1.28-2.40-3.73-21.83-24.94
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses7.007.000.000.00130.000.000.000.000.00
Purchase or Sale of Investments0.000.0020.000.00-92.00-48.39208.63-29.97-96.85
Purchase of Investments0.000.000.000.00-157.46-97.39-19.99-286.39-245.33
Sale Or Maturity of Investments0.000.0020.000.0065.4649.00228.62256.43148.48
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities6.957.0019.93-0.0136.72-50.79204.90-51.80-121.79
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock265.000.0043.690.110.6052.1753.09158.21150.99
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock265.000.0043.690.110.6052.1753.09158.21150.99
Proceedsfrom Stock Options13.490.000.000.000.0051.2051.98157.03150.91
Issuance or Reduction of Debt, Net-11.38-3.127.000.300.000.000.000.000.00
Change in Long Term Debt-11.38-3.127.000.300.000.000.000.000.00
Issuance of Long Term Debt0.000.007.005.500.000.000.000.000.00
Reduction of Long Term Debt-11.38-3.120.00-5.200.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.0044.440.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-8.710.000.000.000.000.000.00
Cash from Financing Activities253.62-3.1295.140.410.6052.1753.09158.21150.99
Net Change in Cash240.55-29.6747.35-18.28-76.35-108.37163.6615.06-13.36
Free Cash Flow-20.07-33.54-67.79-18.68-114.95-112.15-98.06-113.19-67.50
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments289.59106.2750.7548.3049.0454.83
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.473.296.136.751.773.49
Total Current Assets291.06109.5656.8855.0550.8158.32
Net Property, Plant & Equipment5.435.575.836.086.336.58
Total Investments and Advances0.650.650.650.650.650.65
Intangible Assets0.000.000.000.000.000.00
Other Assets0.070.090.330.000.000.57
Total Assets297.20115.8763.6761.7857.7866.12
Short Term Debt Incl. Current Port. of LT Debt0.760.736.956.936.906.88
Accounts Payable1.111.560.650.880.970.91
Other Current Liabilities3.303.103.063.543.233.75
Total Current Liabilities5.175.4010.6711.3511.1111.53
Long Term Debt4.364.566.698.4210.1211.82
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.0055.0055.00
Total Liabilities9.539.9617.3619.7676.2378.35
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity287.67105.9146.3142.01-18.45-12.23
Total Shareholders Equity287.67105.9146.3142.01-18.45-12.23
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity287.67105.9146.3142.01-18.45-12.23
Total Liabilities & Stockholders Equity297.20115.8763.6761.7857.7866.12
Book Value Per Share9.624.463.173.27-1.50-1.00
Tangible Book Value Per Share9.624.463.173.27-1.50-1.00
Full-Time Employees---24--
Price to Book Ratio0.964.021.96-2.21-1.97-4.53
Return on Assets18.1737.1346.5838.70-51.87-54.96
Return on Equity23.9672.14157.18125.06--491.67
Return on Invested Capital-3.06-8.10-14.35114.48--
Quick Ratio56.3320.285.334.854.575.06
Current Ratio56.3320.285.334.854.575.06

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-8.92-8.95-7.6157.73-7.39-9.49
Depreciation0.080.090.090.090.090.09
Other Funds (Non Cash)3.071.931.74-63.811.382.06
Funds from Operations-5.77-6.93-5.78-5.99-5.92-7.34
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.353.85-0.57-0.191.69-3.31
Cash from Operating Activities-4.42-3.08-6.34-6.18-4.23-10.65
Capital Expenditures-0.050.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.007.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.050.000.007.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock187.7966.8510.360.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock187.7966.8510.360.000.000.00
Proceedsfrom Stock Options13.490.000.000.000.000.00
Issuance or Reduction of Debt, Net0.00-8.26-1.56-1.56-1.560.00
Change in Long Term Debt-6.70-1.56-1.56-1.56-1.560.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-6.70-1.56-1.56-1.56-1.560.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities187.7958.598.80-1.56-1.560.00
Net Change in Cash183.3255.522.45-0.74-5.79-10.65
Free Cash Flow-4.47-3.08-6.34-6.18-4.23-10.65

Revenue breakdown

Pharmaceutical Preparations2025: 53.74M
United States2025: 53.74M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3028.89%5.6M19.4M707.10K
2026-10-1529.36%5.7M19.3M771.35K
2026-09-3022.25%4.7M21.0M1.28M
2026-09-1517.97%3.8M21.0M1.17M
2026-08-3116.93%3.6M21.0M1.15M
2026-08-1414.96%3.1M21.0M1.51M
2026-07-3122.34%3.0M13.4M1.48M
2026-07-1518.96%2.3M11.9M1.41M
2026-06-306.47%0.7M10.5M754.89K
2026-06-1512.00%0.9M7.6M737.38K
2026-05-2911.41%0.9M7.6M682.72K
2026-05-156.30%0.6M10.1M296.41K
2026-04-307.65%0.7M8.5M287.17K
2026-04-155.15%0.4M7.4M250.17K
2026-03-316.80%0.4M6.0M223.70K
2026-03-135.80%0.4M6.0M191.97K
2026-02-276.82%0.4M5.3M3.05M
2026-02-136.89%0.4M5.3M3.04M
2026-01-306.64%0.3M4.7M3.02M
2026-01-155.70%0.3M4.7M2.98M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.509.000.000.0000.000.000.0000.0000.000
call5.002.106.300.009.8600.000.000.924-0.1740.002
call7.500.204.801.558.0218480.000.797-0.2010.004
call10.000.003.700.257.22372.000.000.687-0.2070.005
call12.500.000.400.152.26750.000.000.245-0.0580.005
call15.000.000.850.002.9710.000.000.205-0.0690.004
call17.500.003.400.003.4920.000.000.184-0.0750.004
call20.000.003.400.003.9320.000.000.170-0.0810.004
put2.500.003.400.000.0000.000.000.0000.0000.000
put5.000.003.400.0115.5601.000.00-0.071-0.1710.002
put7.500.003.400.308.76869.000.00-0.203-0.2000.004
put10.000.054.301.106.85021.000.00-0.313-0.2060.005
put12.501.105.304.015.2413.000.00-0.755-0.0570.005
put15.003.507.900.006.2380.000.00-0.795-0.0670.004
put17.506.0010.500.007.0470.000.00-0.816-0.0740.004
put20.008.5013.000.007.5630.000.00-0.830-0.0790.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-11-06SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-28SCHEDULE 13GSEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-09SCHEDULE 13GSEC
2026-09-308-KCurrent report2026-09-30SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-28EFFECTEffectiveness filing by commission orderSEC
2026-07-28424B3SEC
2026-07-214/A2026-06-12SEC
2026-07-214/A2026-06-12SEC
2026-07-214/A2026-06-12SEC
2026-07-214/A2026-06-12SEC
2026-07-214/A2026-06-12SEC
2026-07-214/A2026-06-12SEC
2026-07-214/A2026-06-12SEC
2026-07-214/A2026-06-12SEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100045.25K3
2026-090000
2026-0800275.14K3
2026-070000
2026-060000
2026-0530.00M200
2026-040000
2026-030000
2026-020075.42K3
2026-010000
2025-1200109.27K2
2025-110000

Institutional holders

Manager% owned
ORBIMED ADVISORS LLC24.34%
Boxer Capital Management, LLC18.57%
BVF INC/IL13.86%
RA CAPITAL MANAGEMENT, L.P.13.76%
Atlas Venture Life Science Advisors, LLC9.13%
Point72 Asset Management, L.P.6.92%
Opaleye Management Inc.5.49%
Logos Global Management LP4.72%
SummitTX Capital, L.P.4.33%
VANGUARD CAPITAL MANAGEMENT LLC3.06%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND3.16%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.29%
Avantis U.S. Small Cap Value ETF1.71%
Columbia Small Cap Growth Fund1.16%
Multi-Manager Small Cap Equity Strategies Fund0.22%
Ultra-Small Company Fund0.20%
iShares Micro-Cap ETF0.17%
Fidelity Extended Market Index Fund0.17%
Avantis U.S. Small Cap Value Fund0.17%
Fidelity Nasdaq Composite Index Fund0.08%

OakChart. QTTB. Cached 15 minutes.